Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy
The present study investigated the outcomes in different age groups of 101 patients receiving front-line imatinib therapy for chronic myeloid leukemia. Middle-age patients had a significantly greater rate of major molecular response, a superior estimated 6-year event-free survival, and a greater estimated 6-year overall survival rate compared with younger and elderly patients and, consequently, the best long-term treatment outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Irena Ćojbašić, Lana Mačukanović-Golubović, Miodrag Vučić, Ivan Tijanić Tags: Original Study Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Hematology | Leukemia | Lymphoma | Myeloma | Study